Siwei (Shanghai) Biotechnology Co., Ltd.

Development Candidates

管线英文版20200420.jpg

Immuno-Oncology

Personalized Cancer Vaccine (PCV)

Stemirna is developing mRNA-based personalized cancer vaccine. The tumor-specific mutations on patient cancer cell, called neoantigens, are identified via next-generation sequencing. The neoantigens can help the immune system distinguish between tumor cells and normal cells. Using algorithms developed by our bioinformatics team, we predict neoantigens that will elicit a strong immune response and load them onto a single mRNA. After injection, the mRNA vaccine is translated into the desired neoantigens in the patient's dendritic cells and presented by MHC molecules, thereby activating tumor antigen-specific T cells to kill cancer cells.

Intratumoral Immuno-Oncology Therapeutics

Immunological checkpoint inhibitors that are currently available have poor effects on "cold" tumors. mRNA encoding immune activation molecules, combined with checkpoint inhibitors, can activate the tumor immune microenvironment and have a therapeutic effect in "cold" tumors. The treatment works by transforming "cold" tumors of immunosuppressive microenvironment into immune "hot" tumors and enhancing specific anti-tumor T cell response, resulting in a highly effective anti-cancer immune response.

KRAS Cancer Vaccine

KRAS mutations are involved in a variety of lethal tumors such as lung cancer, colon cancer and pancreatic cancer. We designed and synthesized a therapeutic vaccine by loading multiple KRAS mutant antigens onto a single mRNA, targeting multiple tumors involved with KRAS mutations.

EBV Vaccine

EB virus infection can cause nasopharyngeal cancer, gastric cancer, lymphoma, etc. We are designing and developing mRNA vaccines for EB virus, which could activate the human immune system, and prevent EB virus infection, thereby reducing related tumorigenesis.

AML Vaccine

Stemirna are collaborating with Ruijin Hospital to design and develop mRNA vaccines encoding AML mutant antigens in Chinese patients with acute myeloid leukemia (AML). It aims to improve the survival rate of AML patients and improve the prognosis.

Infectious Diseases

Influenza Vaccine

Influenza viruses are highly susceptible to recombination mutations. In traditional influenza vaccines, the target pathogens or antigens must be produced in a specialized cell culture or by fermentation and the discovery and production cycles are long, making it difficulting to prevent a spread. mRNA-based influenza vaccines can be promptly producted and tested, thus significantly shortening the development and production cycles.

MERS-CoV Vaccine

Middle East Respiratory Syndrome coronavirus (MERS-CoV) is a new pathogen with pandemic potential and currently no clinically-approved MERS-CoV vaccine is available. We are designing a mRNA vaccine encoding MERS virus antigens, which can mimic the process by which natural viral infections occur. It aims to stimulate immune response and prevent future MERS infection.

mRNA for iPSC

Cardiovascular Disease

Cardiovascular disease is one of the most common causes of human death. Apart from death, it can also cause irreversible damage in cardiac function. The emergence of induced pluripotent stem cells (iPSCs) technology has made it possible to cure cardiovascular diseases. IPSCs are generated by transfecting fibroblasts with mRNAs encoded reprogramming factors (Oct4, Sox2, c-Myc, and Klf4) and are then induced to differentiate into cardiomyocytes.

About Us
- Our Story
- News Updates
- Contact Us
Platforms
- mRNA Synthesis Platform
- LPP Delivery Platform
- GMP Manufacturing
Pipeline
- Therapeutic Areas
- Development Candidates
Patients
- Clinical Trials
Partnering
- Investors
Join Us
- Opportunities